Tempus AI Inc. (TEM) Report Interpretation

Overview

Goldman Sachs initiates coverage of Tempus AI with a Neutral rating. Its central conclusion is that attractive, relatively visible Diagnostics reimbursement and volume catalysts are counterbalanced by uncertainty over concentrated Data & Applications contracts and whether Tempus can sustain its multimodal-data advantage.

Core views

Tempus operates linked Diagnostics and Data & Applications businesses. Its diagnostic laboratory conducts oncology and hereditary testing and is paid by insurers, Medicare/Medicaid, or patients. The resulting de-identified clinical, molecular, imaging, and outcome data can be licensed to pharmaceutical and biotechnology customers, while its data and algorithms also support trial matching and care-gap identification. Goldman Sachs views this linkage as strategically important: Diagnostics creates the data underlying the higher-margin data business, while data and algorithms can add value to diagnostic and clinical workflows. The report's most visible near-term growth thesis is Diagnostics reimbursement. Following FDA approval of the tumor-only xT companion diagnostic assay, Tempus can place its solid-tumor DNA portfolio under a unified ADLT reimbursement framework. Management expects roughly $200 of ASP uplift and about $85 million of annualized revenue beginning in 2027. Goldman Sachs argues that this improvement applies to an established testing base and should be accretive to profitability because it requires little incremental commercial investment. The next potentially larger catalyst is xF, a blood-based liquid-biopsy therapy-selection assay that is under FDA review and expected to receive approval in 2H27. Management assumes approximately $7,500 reimbursement, versus current reimbursement near $3,200, implying about $550 of ASP uplift. Together, xT and xF could generate about $400 million of incremental revenue by 2028 and strengthen Tempus's therapy-selection position. The report also identifies additional Diagnostics and oncology opportunities. The Personalis-based NeXT Personal MRD assay is already reimbursed in breast cancer, NSCLC, and IO monitoring; further MolDx decisions in colorectal cancer and other tumor types could raise ASPs, improve unit economics, and support wider sales-force deployment. MRD testing rose from approximately 6,500 tests in 1Q26 to 9,000 in 2Q26, or 38% sequentially, while only about 10-15% of the sales force was selling MRD products. Tempus also launched xH, a whole-genome sequencing assay for hematologic malignancies. The pending Personalis acquisition could bring NeXT economics in-house and provide exposure to Moderna and Merck's intismeran program, although Goldman Sachs does not include Personalis revenue in its Tempus estimates and takes no view on whether the transaction closes. Data & Applications is the main offset to the Diagnostics thesis. Diagnostics represents about 75% of revenue and Data about 25%, but the data business is central to the company's long-term strategy. Insights, which licenses de-identified linked datasets and provides modeling, represents more than 80% of the data business and is positioned to benefit from pharmaceutical investment in AI-enabled drug discovery and development. Tempus works with 19 of the top 20 pharmaceutical companies and more than 250 biotechnology companies. However, the report flags that the top five customers still represented about 59% of 2025 revenue, although this improved from 85% in 2020. As several major agreements approach extension decisions over the next one to two years, Goldman Sachs sees risk to the company's mid-term 25% growth guide. The individual contract timelines are material. AstraZeneca's November 2021 agreement includes a $220 million minimum spend through December 31, 2026, with an option for a further $100 million through 2028. GSK's agreement includes $180 million of minimum spend through 2027 and a potential additional $120 million through 2030. Recursion's agreement totals $160 million through 2028 but can be terminated after three years, in November 2026, with notice and an early-termination fee. Goldman Sachs does not forecast whether these agreements will be extended, but argues that successful extensions would support confidence in data-contract stickiness and differentiation. Goldman Sachs recognizes Tempus's first-mover advantage in assembling multimodal data through diagnostics, healthcare-provider relationships, and industry associations. The report says Tempus has invested heavily in legal, IT, data-feed, and AI/ML infrastructure to cleanse and structure EHR-linked data. Yet it does not own the underlying EHR records, and progress in AI/ML may reduce the time needed for new entrants to create comparable datasets. Diagnostic peers, EHR providers, and AI-native companies could access similar records; peers including Guardant, Natera, Caris, and Roche are pursuing related data-monetization strategies. The report therefore views long-term moat durability as an unresolved debate despite Tempus's data quality, relationships, and attractive gross margins. Goldman Sachs forecasts revenue rising from $1,593.4 million in 2026E to $1,963.6 million in 2027E and $2,372.6 million in 2028E. EBITDA is projected to increase from $98.2 million in 2026E to $130.2 million in 2027E and $237.5 million in 2028E; EBIT is projected to turn positive in 2027E. For valuation, Tempus trades at about 8x 2027 EV/Sales, around 4x below the peer median. Goldman Sachs applies a 5x discount to peers, using 7x 2027-2028 sales, to derive its $75 12-month target, or roughly 4% downside from then-current levels. The discount reflects the balance between Diagnostics catalysts and the risks around data contracts and competitive durability.

Analysis framework

Goldman Sachs first assesses Tempus's two linked operating segments, then evaluates specific Diagnostics reimbursement and product catalysts, Data & Applications growth drivers and contract concentration, and the durability of the company's multimodal-data advantage. It concludes with forecast financials and a peer-relative EV/Sales valuation that incorporates a discount for data-business uncertainty.

Methodology notes

• Valuation methods

  Peer-relative EV/Sales valuation

  Goldman Sachs compares Tempus's 2027 EV/Sales multiple with a peer median and applies a discount to reflect contract-renewal and competitive risks, producing a 7x 2027-2028 sales valuation basis and $75 target price.

• Industry AnalysisUpstream-Midstream-Downstream Transmission

  Diagnostics-to-data business linkage

  The report examines how diagnostic testing generates de-identified multimodal data that can be licensed to pharmaceutical customers and used in clinical-trial and algorithmic applications.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Tempus AI Inc. (TEM.US)

  Primary subject; Diagnostics reimbursement catalysts are balanced by Data & Applications contract and competitive risks.

  Strengths

  xT reimbursement uplift, potential xF approval and pricing, linked Diagnostics-data platform, and leading multimodal-data collection capabilities.

  Weaknesses

  Customer concentration, uncertain contract extensions, and lack of exclusive EHR-data rights.

  Comparison

  Trades at about 8x 2027 EV/Sales, approximately 4x below the comparable peer median; Goldman Sachs applies a discount to peers.

  Risks

  Slower reimbursement, delayed AI monetization, competition in genomics and oncology data, and non-renewal of large data contracts.

• Personalis (PSNL.US)

  Pending acquisition target and current NeXT MRD testing partner for Tempus.

  Strengths

  Its ImmunoID NeXT platform supports individualized neoantigen therapy programs and could expand Tempus's MRD economics.

  Weaknesses

  Its contribution is not included in Goldman Sachs's Tempus estimates.

  Risks

  The report takes no view on whether the acquisition closes.

Key data

• 12-month price target$75.00Neutral initiation; versus $77.84 current price and 3.6% stated downside.
• xT reimbursement benefit~$200 ASP uplift and ~$85 million annualized revenueExpected to begin in 2027 following FDA approval and ADLT reimbursement migration.
• xF assumed reimbursement~$7,500Expected after potential 2H27 FDA approval, versus current reimbursement near $3,200; estimated ~$550 ASP uplift.
• Combined xT and xF opportunity~$400 million incremental revenueManagement estimate by 2028.
• Top-five customer concentration~59% of 2025 revenueDown from 85% in 2020; large contract renewals remain important.
• MRD testing volume~9,000 tests in 2Q26Up from ~6,500 in 1Q26, representing 38% quarter-on-quarter growth.
• 2028E revenue and EBITDA$2,372.6 million and $237.5 millionGoldman Sachs forecasts, compared with $1,593.4 million revenue and $98.2 million EBITDA in 2026E.
• Valuation basis7x 2027-2028 salesDerived from a 5x discount to peers; Tempus traded at about 8x 2027 EV/Sales.

Impact & implications

The report argues that reimbursement-led Diagnostics growth can improve revenue and margins with limited added commercial spending, while Data & Applications remains the longer-term strategic value driver. Contract extensions, data-business execution, and evidence that the multimodal-data moat can withstand competition are needed to reduce the uncertainty underlying the Neutral rating.

Risks

• Slower MolDx coverage, adverse pricing, or slower payer adoption could delay revenue and returns from MRD and new assays.
• AI-enabled diagnostic tools and algorithms may take longer to monetize if reimbursement support develops slowly.
• Competition from genomics, diagnostics, EHR, and AI-enabled data providers could pressure market share, pricing, and growth.
• Failure to renew or extend large data contracts could materially affect the Data business growth outlook.

What to watch

• xF FDA approval and potential ADLT pricing in 2H27.
• xT reimbursement implementation and the resulting 2027 ASP and revenue uplift.
• Additional MolDx coverage decisions and MRD commercial adoption.
• AstraZeneca, GSK, and Recursion contract-extension or termination decisions.
• Broader deployment of Tempus's AstraZeneca multimodal foundation model and other pharmaceutical data partnerships.
• Progress on the pending Personalis acquisition and the development of the intismeran opportunity.
• Algorithm adoption, reimbursement pathways, and monetization progress.